ABSTRACT
The location and functional role of histamine H 4 receptors (H 4 Rs) in the gastrointestinal tract (GI) is reviewed, with particular reference to their involvement in the regulation of gastric acid secretion, gastric mucosal defense, intestinal motility and secretion, visceral sensitivity, inflammation, immunity and carcinogenesis. H 4 Rs have been detected in different cell types of the gut, including immune cells, paracrine cells, endocrine cells and neurons; moreover, H 4 R expression was reported in human colorectal cancer specimens. Functional studies with selective H 4 R ligands demonstrated protective effects in several experimental models of gastric mucosal damage and intestinal inflammation, suggesting a potential therapeutic role of drugs targeting this new receptor subtype in GI disorders, such as allergic enteropathy, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and cancer.
INTRODUCTION
Histamine is a pleiotropic biogenic amine with a broad range of activities in both physiological and pathological conditions. Both histamine producing cells and receptors are extensively distributed within the body, suggesting that this amine is an important regulator of a wide variety of functions. Despite the intestinal effects of histamine were firstly described one century ago in the landmark paper by Dale and Laidlaw (1), research mainly focused on immunological and inflammatory effects of this amine, leading to the discovery of the histamine H 1 receptor (H 1 R) antagonists, as the first anti-allergic drugs (2). In 1972, thanks to the pioneering work of Sir James Black and coworkers, the central role of histamine in the regulation of parietal cell acid secretion was clearly defined and histamine H 2 receptor (H 2 R) antagonists became the standard therapy of gastric acid related diseases (3-5). Since then, two further receptor subtypes have been discovered, namely H 3 and H 4 , and the research on histamine gained considerable interest again (6-12). Therapeutic fields have emerged for H 3 receptor (H 3 R) ligands, with selective antagonists representing new drugs for cognitive, sleep and memory disorders (13, 14) and for obesity (15); on the other hand, based on the predominant location of H 4 receptors (H 4 Rs) in immune and inflammatory cells, selective antagonists of this receptor are currently the object of intensive research, as potential candidates in the therapy of allergy, inflammatory disorders, neurophatic pain and pruritus (16) (17) (18) (19) (20) (21) . A large body of evidence has unraveled the occurrence of H 4 Rs in the gastrointestinal (GI) tract, together with protective effects mediated by H 4 R ligands in experimental models of GI damage, thus suggesting that this novel receptor subtype might represent a potential drug target in the treatment of functional GI diseases.
In the present review we report the available data concerning the location and functional role of histamine H 4 Rs in the GI tract and the potential clinical implications for human diseases.
HISTAMINE IN THE GI TRACT: CELLULAR SOURCES, TARGETS AND RECEPTORS
In the GI tract, histamine is synthesized by histidine decarboxylase (HDC) enzyme and stored in various cell types, including mast cells, basophils, and enterochromaffin-like (ECL) cells; few reports suggest the occurrence of histamine in G cells and enteric neurons (Figure 1) (22-26) . In addition, several myeloid and lymphoid cell types (dendritic cells, neutrophils, monocytes/macrophages, T cells and platelets), which do not store histamine, show high HDC activity and are capable of producing histamine to a varying degree, following activation by allergens, mitogens or cytokines (27-30). Finally, most malignant cells contain high concentrations of histamine that can regulate tumour growth via a paracrine or autocrine pathway (Figure 1 ) (31). Histamine stores greatly vary among species: in dogs and humans, mast cells account for the major histamine content; they are predominantly located in the mucosal surfaces of the whole GI tract and are mainly involved in IgE-mediated hypersensitivity in response to allergens and in reactions against parasites (32). In rodents, ECL cells are recognized as the major histamine-producing cells in the gastric mucosa, thereby representing a central regulatory pathway for the secretion of acid via the parietal cell (33, 34). Elevated concentrations of histamine have been shown in various inflammatory and neoplastic diseases, such as Crohn's disease, ulcerative colitis, irritable bowel syndrome (IBS), allergic enteropathy and colorectal cancer (32, 35-38).
In the GI tract, histamine plays a role in a number of processes, including acid secretion, mucosal defense, fluid transport, neurotransmission, inflammation, immunity and carcinogenesis, targeting a variety of cell types ( Figure  1 ) (28, 31, 32, 39-42). These different biological functions involve the four known histamine receptor subtypes, identified to date, H 1 , H 2 , H 3 and H 4 , which are differently expressed along the gut. Histamine H 1 Rs mediate vasodilatation and increase in vascular permeability, smooth muscle contraction, intestinal fluid transport and visceral sensitivity; H 2 Rs are mainly responsible for the physiological regulation of acid secretion from parietal cells, but also influence intestinal 
EXPRESSION OF H 4 Rs IN THE GI TRACT
In the last decade, the occurrence of H 4 Rs in the GI tract of different species, including humans, was demonstrated by the use of several techniques, such as quantitative reverse transcription-polymerase chain reaction (qRT-PCR), Western blot analysis and immunostaining (summarized in Table 1) (7-12, 47-59). Under physiological conditions, H 4 R expression is rather low, as compared with bone marrow, spleen or liver, but it may be regulated by inflammatory stimuli. A recent study demonstrated a significant increase in H 4 R density after treatment of mice with trinitrobenzenesulphonic acid (TNBS), a widely used model of inflammation, which reproduces human Crohn's disease (56, 60). More recently, it was reported that H 4 R expression increases in the colon of mice genetically deficient of the Gi protein alpha2 subunit and the increase in receptor density parallel the colitis progression (61) . The presence of H 4 Rs was demonstrated in the human normal intestine and their distribution pattern was described in detail by histological analysis (49, 51, 53); H 4 R staining was detected in leukocytes inside the small mucosal and submucosal vessels, neuroendocrine cells and, finally, in enterocytes at the apical end of the crypts of Lieberkun (51). The same study reported an increased expression of both H 1 Rs and H 2 Rs in patients with IBS or food allergies, with no change in H 4 R mRNA levels (51). By contrast, H 4 R expression was found to be reduced in colorectal cancer specimens, as compared to normal colonic tissue (49, 53).
HISTAMINE H 4 R SELECTIVE LIGANDS
Since the cloning of the H 4 R, a variety of ligands have been identified in search of selective tools to unravel H 4 R-mediated tissue functions and of potential drug candidates (18) (19) (20) 62) . In accordance with the high homology between H 4 R and H 3 R, most of the firstgeneration H 3 R ligands (like imetit, immepip, thioperamide and clobenpropit) are now known to bind to the H 4 R (16). The first highly selective histamine H 4 R antagonist, namely JNJ7777120, was developed by Johnson and Johnson Pharmaceuticals and it became the reference antagonist for pharmacological investigation, displaying more than a thousand fold selectivity over other receptor subtypes (19, 63, 64) . Other H 4 R antagonists were developed by academic research groups and by several pharmaceutical companies (58, 62, 65, 66) . Histamine H 4 R agonists were also described, such as 4-methylhistamine and VUF8430; these compounds, however, still retain affinity for the other histamine receptor subtypes (67, 68) . To complicate matters, the selectivity profile of most H 4 R ligands was found to greatly vary according to the species; in addition, some ligands were found to behave as "protean" ligands, displaying antagonism, partial, total or inverse agonism activity, depending on the experimental assay (69, 70) . This hampers a clear understanding of H 4 R pharmacology; in line with this, some studies were unable to ascribe the observed effects to agonism or antagonism at H 4 Rs (71, 72) . To support this, a recent study in rats reported that ischemia/reperfusion liver injury was reduced by H 4 R stimulation and not blockade, as expected from the supposed inflammatory activity mediated by H 4 Rs (73).
EFFECTS OF H 4 R LIGANDS IN THE GI TRACT
Several studies have reported functional effects of H 4 R ligands in both in vitro assays and in intact animals. Most data were obtained in rodents by the use of the reference H 4 R antagonist JNJ7777120 (Tables 2 and 3 ).
Gastric acid secretion
The major role of histamine and of H 2 Rs in the stomach is the regulation of acid secretion by the parietal Early studies have reported a low H 4 R expression in the human and rat stomach (Table 1) ; recently, more detailed information about the cell distribution of H 4 Rs in the rat gastric mucosa was obtained by immunohistochemistry (55). In particular, as opposed to H 3 Rs, H 4 Rs do not occur in ECL cells and seem to be selectively located in endocrine cells (A-like cells) of the fundic mucosa producing the orexigenic peptide ghrelin (55). Functional experiments obtained in our lab in the anaesthetised rats with lumen-perfused stomach showed that the selective H 4 R antagonist JNJ7777120 and its benzimidazole derivative VUF6002 (76) did not modify basal acid secretion or the hypersecretion induced by histamine; in addition, only JNJ7777120 reduced the acid secretion induced by pentagastrin (M. Adami, unpublished observations). The hypothesis of gastric secretory effects induced by H 4 R activation, was not confirmed by the use of the H 4 R agonist VUF8430, since the increase in acid secretion induced by this compound was fully prevented by the H 2 R antagonist ranitidine and not by JNJ7777120 (77) . In conclusion, the relevance of histamine H 4 Rs in parietal cell function is still to be elucidated.
Gastric mucosal defense
As opposed to the key role played by histamine in the regulation of parietal cell function, its role in gastric mucosal defense has long been debated, since H 1 R or H 2 R selective ligands displayed either ulcerogenic or protective effects (44). The discovery of histamine H 3 Rs and the use of (R)-alpha-methylhistamine and thioperamide have highlighted the protective effect of histamine in the gastric mucosa, since H 3 R activation prevented the acute mucosal damage induced in rats by absolute ethanol, non-steroidal anti-inflammatory drugs, ammonia, concentrated HCl or stress (78) (79) (80) (81) (82) (83) . The protective effect was related to increase in mucus production, gastric mucosal blood flow, epithelial cell proliferation and activation of sensory nerves (83) (84) (85) .
Data from our group have suggested a possible involvement of H 4 Rs in histamine-mediated effects on mucosal defense (86); HCl-induced gastric lesions were not reduced by immepip and imetit, two formerly described as highly selective H 3 R agonists, which are now known to display considerable affinity at histamine H 4 Rs (16, 67). Indeed, subsequent data from our lab obtained with the selective H 4 R antagonist JNJ7777120, would indicate that H 4 Rs are involved in the ulcerogenic effects of histamine (71, 87) . This compound was found to protect the rat and mouse gastric mucosa from the damaging effect of non steroidal anti-inflammatory agents and the mast cell degranulator compound 48/80 (Table 3) . However, preliminary experiments from our group showed that in rats, but not in mice, the selective H 4 R agonist VUF8430 significantly reduced indomethacin-induced lesions ( Figure  2 , Table 3 ) (71) . From the available data, it is difficult to make a clear picture of the functional role of H 4 Rs in the rat gastric mucosa, due to the similar behaviour displayed by H 4 R agonists and antagonists. The occurrence of H 4 Rs in endocrine cells of the rat fundus producing ghrelin (55, 88) could lead to speculate a possible role of histamine in the secretion of this peptide (Figure 3 ). In line with this, a link between histamine and ghrelin was indicated by recent data from our group, showing that ghrelin-induced gastroprotection is prevented by both H 3 R and H 4 R antagonists (89).
Intestinal motility and secretion
The intestinal effects of histamine were among the first effects of histamine described by Dale and Laidlaw (1). Nevertheless, most attention was devoted to the functional activity of histamine in the stomach and the effects on the bowel were disregarded. In the recent years, it has become apparent that intestinal mast cell mediators and enteric nervous system are key players in the intricate neuroimmune network, that regulates intestinal homeostasis and the inflammatory response to noxious stimuli (90) . Histamine can influence neurotransmission at both submucous and myenteric plexus, thereby modifying intestinal secretion and motility, through the activation of the three receptors H 1 , H 2 and H 3 (32, 39, 45, 46, [91] [92] [93] . The occurrence of a new receptor subtype in the intestine was firstly hypothesized by Schworer et al (94) , who identified in the porcine small intestine an H 3 -like receptor . On the ordinate, macroscopic damage reported as lesion index in mm. Differences among multiple groups were made by using one-way analysis of variance (ANOVA), followed by Dunnett's test: *p < 0.05 and **p < 0.01 compared to the vehicletreated group. Mean values ± SEM from 6-8 rats.
that was pharmacologically distinct from the proposed H 3a and H 3b receptors. These findings were subsequently confirmed by Oda et al (8), who characterized a new histamine receptor (called GPRv53) expressed in the small intestine, and afterwards by several independent groups (Table 1) (7-12).
Despite the presence of H 4 Rs in the rodent myenteric plexus (52), the role of this receptor in the regulation of intestinal motility is apparently absent. In our lab, we were unable to detect any effect of either agonists or antagonists of H 4 Rs on cholinergic neurotransmission in the isolated rat duodenum (95) . Likewise, histamine H 4 R ligands did not modify spontaneous or electrically-evoked motility in surgical specimens from human colon, suggesting that this receptor subtype does not play a role in the regulation of intestinal muscle contractility in humans ( Table 2 ).
The stimulatory effects of histamine on intestinal transport were widely demonstrated in guinea pigs and humans (32, 92, 93, 96, 97) . However, the receptor involved seems to differ across species: in the guinea pig, histamine increases intestinal ion and water secretion in both small and large intestine, via activation of H 2 Rs located on epithelial cells and on colonic submucous plexus (96). In addition, prejunctional H 3 Rs negatively modulate cholinergically-mediated intestinal secretion by removing the inhibitory control exerted by the adrenergic system (96) . As opposed to animal findings, in the human intestine, histamine-induced increase in chloride secretion by colonic epithelium was exclusively related to activation of H 1 Rs (92) . A recent study in human submucous plexus from surgical specimens suggests, however, that histamine may induce excitation of enteric neurons through activation of all four histamine receptors (H 1 R-H 4 R) (98) . The H 3 R- In the rat gastric mucosa the effects of ghrelin on mucosal protection are mediated by both the growth hormone secretagogue receptor type 1a (GHS-R1a) and the H 3 R, suggesting the involvement of histamine in ghrelin-induced protection.
mediated excitatory effects on secretory neurons reported in this study are unexpected, in view of data from the literature showing lack of H 3 R expression in the human bowel or of H 3 R-mediated effects on intestinal contractility (51, 99). The pathophysiological significance of the excitatory action of histamine on secretory neurons is uncertain; hyperactivity of these neurons leads to neurogenic secretory diarrhoea, as observed in various pathological conditions, such as ulcerative colitis, Crohn's disease, allergic enteropathy or parasitic infection (90) . In this connection, mast cells in colonic mucosal biopsies from IBS patients with diarrhoea release more histamine than in normal subjects (37); thus, it can be speculated that H 4 R antagonists may be of therapeutic value in these GI disorders, as observed for mast cell stabilizers or H 2 R antagonists (100, 101).
Visceral sensitivity
Visceral hypersensitivity is widely accepted as a mechanism that can explain many clinical symptoms associated with organic and functional bowel diseases (90, 102) . Histamine, as other inflammatory mediators, has an important role in GI hypersensitivity reactions; once released from mast cells, it can easily reach the afferent sensory nerves nearby and activate neuron discharge, thus increasing visceral sensitization to painful stimuli (103) . In line with this, treatment with mast cell stabilizers prevents lowering of pain threshold, which occurs during mucosal inflammation (90) . According to the species, H 1 R, H 2 R or H 3 R subtypes have been involved in the alteration of visceral pain perception induced by histamine (104-107). As opposed to the early studies, it is now clear that H 4 Rs are expressed and are functionally active on neurons of the mammalian central and peripheral nervous system (52, 98, [108] [109] [110] . To the best of our knowledge, no study has examined to date whether H 4 Rs are located on afferent fibers of the enteric nervous system; in view of the inhibitory effects of H 4 R antagonists in different pain models, it might be of interest to explore the effects of H 4 R ligands in models of visceral pain (65, (111) (112) (113) .
Inflammation and immunity
Accumulating evidence has suggested that histamine plays a key role in inflammation, immediate hypersensitivity reaction and cellular and humoral immune response (28, 30, 41). Preformed or neosynthesized histamine is produced during inflammatory response in several GI disorders, such as food allergy, IBD and IBS, and exerts multiple regulatory effects through the activation of both H 1 Rs and H 2 Rs (32, 37, 41, 114-116). However, the efficacy of medical therapy based on the use of antihistamines or mast cell stabilizers is unproven (115). The recent discovery of H 4 Rs, mainly located in immune and inflammatory cells has further strengthened the role of histamine at this level. Given the ability of H 4 Rs to modulate the function of mast cells, T cells, dendritic cells and eosinophils, it is natural to foresee a therapeutic potential of H 4 R antagonists in inflammatory disorders of the GI tract. Indeed, both in vitro and in vivo studies provided evidence for a beneficial effect of H 4 R antagonists as anti-inflammatory agents (Tables 2 and 3) . Histamine H 4 R antagonists were effective against the intestinal damage induced in rats by TNBS, a hapten which induces in rodents many of the macroscopic, histological and immunological hallmarks of the human IBD (60) . In this assay, oral administration of JNJ7777120 produced a significant inhibition of macroscopic damage, neutrophil infiltration and the increase in TNFalpha and IL-6, two cytokines that play a critical role in the pathogenesis of the human disease (117) (118) (119) (120) . Other studies have confirmed the inhibitory effects of H 4 R antagonists on neutrophil influx into peritoneal cavity or into the pleural cavity (65, 121) . JNJ7777120 was partially effective in reducing zymosaninduced peritonitis, a model of acute inflammation which is reported to be mast cell-dependent, since the neutrophil influx induced by zymosan is reduced in mast cell-deficient mice (64, 122) . The observation that the H 4 R antagonist was ineffective in the peritonitis induced by thioglycollate (a mast cell-independent model) is consistent with the hypothesis than JNJ7777120 is acting on mast cells (64, 122) . In line with this, analysis of peritoneal cell exudate in mice unraveled an expression of H 4 R mRNA higher in naive animals, as compared to genetically modified mice, devoid of mast cells, suggesting that resident mast cells may be the predominant H 4 R-expressing cell in the peritoneum (113) . Finally, the involvement of H 4 Rs in the ischemia/reperfusion-induced damage was recently reported in mice (123) ; this findings, however, were obtained with the H 3 /H 4 receptor blocker thioperamide, thus the evidence for a specific involvement of H 4 Rs is lacking; in line with this, previous data obtained in rats showed that the effect of histamine on intestinal ischemia was related to activation of H 1 Rs (124).
Carcinogenesis
The stimulatory effect of histamine on tumor growth has been known for long time (31). High levels of HDC activity and high concentrations of histamine have been detected in both experimental and human tumours, such as breast cancer, melanoma, small cell lung carcinoma, endometrial cancer and colorectal carcinoma (38, 49, (125) (126) (127) (128) (129) . In addition, histamine content was correlated with the presence of lymph node and/or distant metastasis in colorectal cancer (49). Histamine was reported to act also as an angiogenic factor and induce vascular endothelial growth factor (VEGF) production, thus influencing the process of tumour invasion and metastasis (130, 131) . The tumour promoting effects of histamine appear to be predominantly mediated by H 2 Rs; in line with this, some encouraging results of clinical trials have shown increased survival of gastric and colon cancer patients after treatment with the H 2 R antagonists cimetidine and ranitidine (132) (133) (134) . The recent discovery that histamine H 4 R expression was detected in colorectal specimens has renewed the interest for the role of histamine in carcinogenesis and opened new horizons in this field. A recent study investigated the distribution of the different histamine receptor subtypes in the colorectal tumours compared to the normal mucosa, by different techniques such as RT-PCR, Western blot analysis and immunostaining (98) . The study demonstrated the presence of H 1 R, H 2 R and H 4 R expression in adenoma and human colon carcinoma at protein level; in addition, in line with previous studies ruled out the presence of H 3 Rs in the human intestinal tissue (49, 51, 99). Histamine receptor expression pattern in neoplastic tissue was altered as compared to normal colonic mucosa, with significantly reduced expression of both H 1 Rs and H 4 Rs in tumour (98); this could favour H 2 R-mediated regulation of tumour cell growth. Further studies are required to clarify whether H 4 R downregulation has relevance in tumour progression and whether agonism at H 4 Rs combined to H 2 R antagonism would shift the process in the direction of tumour inhibition. It is of interest that H 4 R activation reduced cell proliferation in a pancreatic carcinoma cell line and in human hematopoietic progenitor cell (135, 136) . Recently, however, it was reported that the H 4 R antagonist JNJ7777120 and the H 2 R antagonist zolantidine prevented the effects of histamine on cell proliferation, VEGF production and cyclooxygenase-2 (COX-2) induction in several colon cancer cell lines, without affecting basal cell proliferation (49). Collectively, these findings suggest that further studies are needed to assess the role of H 4 Rs on tumor cell growth.
SUMMARY AND PERSPECTIVE
Over the past few years research on histamine H 4 Rs has provided significant evidence for a role of this new receptor in a variety of histamine functions, emphasizing the concept that there is still much to learn about histamine and its versatile biology. The findings reviewed here strongly suggest that histamine H4Rs may participate in the GI effects of histamine; H 4 R expression was found in different cell types and can vary under pathological conditions characterized by inflammation and malignancies. The beneficial effects demonstrated by H 4 R antagonists in several models of GI mucosal damage, would lead to conclude that the H 4 R could be a potential target candidate in the therapy of functional GI diseases. However, further studies with more selective ligands are needed to characterize the GI H 4 R under both physiological and pathological conditions. This would be of utmost importance, when considering that H 4 R antagonists are being proposed as new anti-inflammatory/anti-allergic drugs and that most of the therapeutically available drugs for inflammation and pain are endowed with significant gastric and intestinal toxicity (137, 138) .
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